Clinical trial
Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
NCT00193180 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193180 |
|---|---|
| Title | Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer |
| Official title | Phase II Trial of Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Novartis Industry Aventis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Imatinib, Docetaxel |
| Enrollment | 37 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | May 27, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: